Mpox Updates Amidst the Ongoing Global Public Health Emergency
Registration Details
- Preregistration: $0.00 (USD)
- Preregistration ends: Wednesday, November 13, 2024
You must Login or Create Account in order to register for this event
Presenter
Moderator
November 13, 2024
10:00 AM – 11:15 AM PTOverview
Assessment of Needs
In August 2024, a new variant of mpox (clade 1b) that is behind a growing number of cases in several countries in Africa (including the Democratic Republic of Congo, Burundi, the Central African Republic, and Rwanda) led the Africa Centres for Disease Control and Prevention to declare a public health emergency. Shortly thereafter, the World Health Organization declared that the surge in mpox constituted an international public health emergency. This webinar provides an update on what clinicians need to know regarding mpox, particularly the latest guidance in clinical recognition, management, and treatment, including current and ongoing research and gaps in knowledge.
Learning Objectives
On completion of this activity, learners will be able to:
- Discuss what we knew about mpox before the 2022 mpox outbreak
- Describe what we learned about testing, treatment, and vaccination since the 2022 clade IIb mpox outbreak
- Identify similarities and differences between clade IIb and clade I, responsible for the newly called public health emergency of international concern
- Summarize what is still unknown and what is needed to address these knowledge gaps
Registration
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Wednesday, November 13, 2024, 10:30 AM (PT).
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Presenter
Dr Zucker reported no financial relationships with ineligible companies. (Updated December 31, 2023)
Moderator
Dr Currier reported consulting or advisor fees from Merck & Co, Inc. (Updated August 24, 2023)
Planner/Reviewer
Planner/Reviewer 1 reported no relevant financial relationships with ineligible companies (Updated September 15, 2024)
Planner/Reviewer 2 reported no relevant financial relationships with ineligible companies (Updated September 15, 2024)
COW Board
The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
This program is approved for 1.25 hours of pharmacotherapy credit.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-24-370-L02-P
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
PLATINUM SUPPORTERS
Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.